Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma
Investigative Opthalmology & Visual Science · 2023-08-21 · 64 (11) · 27
DOI: 10.1167/iovs.64.11.27 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, published on 2023-08-21. Written by Zhao Xun Feng and 4 co-authors. Institution: Department of Ophthalmology, University of Ottawa, Ottawa, Canada. Major MEDLINE topics: Retinal Neoplasms, Retinoblastoma. Cited 12 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0).
Topics: Onkologische Pflege, Kinderkrankenpflege
Abstract (original language)
Purpose
The purpose of this study was to investigate the effect of adjuvant chemotherapy on outcomes of children with massive choroidal invasion (MCI).
Methods
In this study, we reviewed the 5-year relapse-free survival (RFS) and overall survival (OS) of children diagnosed with MCI, managed with or without adjuvant chemotherapy. Excluded were children with additional other high-risk features (post-laminar optic nerve invasion, scleral invasion, or overt extraocular disease).
Results
Of 3566 children diagnosed with retinoblastoma, 2023 had enucleation, and 60 eyes of 60 children had pathology showing MCI without concomitant high-risk features. Enucleation was primary (22, 37%), or secondary (38, 63%) after failed eye salvage. Adjuvant systemic chemotherapy (median = 4, range = 1-8 cycles) was given to 48 of 60 (80%) children; 12 of 60 (20%) children had no adjuvant therapy. Five-year RFS was 88.5% (95% confidence interval [CI] = 79.7%-97.3%) and 5-year OS was 90.1% (95% CI = 81.7%-98.5%). Pre-enucleation chemotherapy did not affect RFS (89.7% vs. 75.0%; P = 0.657). Adjuvant chemotherapy improved RFS (97.2% vs. 55.6%; P < 0.001) and OS (97.2% vs. 66.7%; P < 0.001). In subgroup analysis, adjuvant chemotherapy improved RFS for both primarily enucleated (5-year RFS 100% vs. 50.0%; P = 0.002) and secondarily enucleated children (5-year RFS 95.8% vs. 60.0%; P = 0.005). The number of children treated with adjuvant chemotherapy to prevent one post-enucleation systemic relapse or death is three.
Conclusions
Adjuvant chemotherapy significantly decreased the risk of tumor relapse and death for children with pathological MCI. For every three children treated with adjuvant chemotherapy, one systemic relapse or death could be prevented.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Ophthalmology, University of Ottawa, Ottawa, Canada.
- Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Department of Pathology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Department of Medical Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Beijing, China.
Cite
APA
Feng, Z. X., Zhao, J., Zhang, N., Jin, M., & Gallie, B. (2023). Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma. Investigative Opthalmology & Visual Science, 64(11), 27. https://doi.org/10.1167/iovs.64.11.27
Vancouver
Feng ZX, Zhao J, Zhang N, Jin M, Gallie B. Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma. Investigative Opthalmology & Visual Science. 2023;64(11):27. doi:10.1167/iovs.64.11.27
BibTeX
@article{Feng2023,
author = {Feng, Zhao Xun and Zhao, Junyang and Zhang, Nan and Jin, Mei and Gallie, Brenda},
title = {Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
volume = {64},
number = {11},
pages = {27},
doi = {10.1167/iovs.64.11.27}
}
EUVIMED